Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb slashed about 25% of its sales force for the antipsychotic Abilify on Friday.
The job cuts resulted from an evaluation the New York drug maker conducted after it extended its co-marketing pact with Otsuka Corp. for Abilify earlier this year. Most major drug companies have steadily reduced their sales forces in recent years to save costs and address doctors' complaints that they were being bombarded by too many sales representatives. The company declined to specify how many jobs were cut, saying the size of its Abilify sales force was proprietary.

Oct 16 · 11:18:00 AM · Source: The Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto